Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010–2018

Abstract

by Sikha Singh,Jelili Ojodu,Alex R. Kemper,Wendy K. K. Lam andScott D. Grosse
Int. J. Neonatal Screen. 2023, 9(2), 20; https://doi.org/10.3390/ijns9020020 - 6 Apr 2023
Cited by 11 | Viewed by 3163
Abstract
The Recommended Uniform Screening Panel (RUSP) is the list of conditions recommended by the US Secretary of Health and Human Services for inclusion in state newborn screening (NBS). During 2010–2022, seven conditions were added to the RUSP: severe combined immunodeficiency (SCID) (2010), critical congenital heart disease (CCHD) (2011), glycogen storage disease, type II (Pompe) (2015), mucopolysaccharidosis, type I (MPS I) (2016), X-linked adrenoleukodystrophy (X-ALD) (2016), spinal muscular atrophy (SMA) (2018), and mucopolysaccharidosis, type II (MPS II) (2022). The adoption of SCID and CCHD newborn screening by programs in all 50 states and three territories (Washington, D.C.; Guam; and Puerto Rico) took 8.6 and 6.8 years, respectively. As of December 2022, 37 programs screen for Pompe, 34 for MPS I, 32 for X-ALD, and 48 for SMA. The pace of implementation based on the average additional number of NBS programs per year was most rapid for SMA (11.3), followed by CCHD (7.8), SCID (6.2), MPS I (5.4), Pompe (4.9), and X-ALD (4.7). Full article
► Show Figures
15 pages, 260 KiB
Open AccessArticle